rs11295266 - RN7SKP93 - MGAT5
Magnitude 4.5 · 1 study on file
Reported associations
-
Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand‐foot syndrome - Unknown journal (n.d.) · Unknown authors · PubMed 35467766
ABSTRACT: Abstract Cancer patients treated with capecitabine and oxaliplatin (XELOX) often develop hand‐foot syndrome (HFS) or palmar‐plantar erythrodysesthesia. Genetic variation in ST6GAL1 is a risk factor for type‐2 diabetes (T2D), a disease also associated with HFS. We analysed genome‐wide association data for 10 toxicities in advanced colorectal cancer (CRC) patients from the COIN and COIN‐B trials. One thousand and fifty‐five patients were treated with XELOX ± cetuximab and 745 with folinic acid, fluorouracil and oxaliplatin ± cetuximab. We also analysed rs6783836 in ST6GAL1 with HFS in CRC patients from QUASAR2. Using UK Biobank data, we sought to confirm an association between ST6GAL1 and T2D (17 384 cases, 317 887 controls) and analysed rs6783836 against markers
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
XELOX chemotherapy diarrhea risk Moderate
This variant is associated with increased risk of severe diarrhea during XELOX (capecitabine-oxaliplatin) chemotherapy for colorectal cancer
Before starting XELOX, discuss increased diarrhea risk and prevention strategies with your oncologist